Hepatitis Monthly

Published by: Kowsar

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin

Zaigham Abbas 1 , * , Ghiasun Nabi Tayyab 2 , Mustafa Qureshi 1 , Mohammad Sadik Memon 3 , Amna Subhan 1 , Tanzila Shakir 1 , Wasim Jafri 1 and Saeed Hamid 1
Authors Information
1 Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan
2 Postgraduate Medical Institute, Lahore, Pakistan
3 Department of Medicine, Isra University Hospital, Hyderabad, India
Article information
  • Hepatitis Monthly: December 2013, 13 (12); e14146
  • Published Online: December 14, 2013
  • Article Type: Research Article
  • Received: August 11, 2013
  • Revised: October 2, 2013
  • Accepted: November 17, 2013
  • DOI: 10.5812/hepatmon.14146

To Cite: Abbas Z, Tayyab G N, Qureshi M, Memon M S, Subhan A, et al. Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin, Hepat Mon. 2013 ;13(12):e14146. doi: 10.5812/hepatmon.14146.

Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007; 13(17): 2436-41
  • 2. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4): 1335-74[DOI][PubMed]
  • 3. Gonzalez SA, Keeffe EB. Management of chronic hepatitis C treatment failures: role of consensus interferon. Biologics. 2009; 3: 141-50[PubMed]
  • 4. Horoldt B, Haydon G, O'Donnell K, Dudley T, Nightingale P, Mutimer D. Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection. Liver Int. 2006; 26(6): 650-9[DOI][PubMed]
  • 5. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011; 55(2): 245-64[DOI][PubMed]
  • 6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286): 958-65[PubMed]
  • 7. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13): 975-82[DOI][PubMed]
  • 8. Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5): 346-55[PubMed]
  • 9. Keeffe EB. Chronic hepatitis C: management of treatment failures. Clin Gastroenterol Hepatol. 2005; 3(10 Suppl 2)-5[PubMed]
  • 10. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology. 2009; 136(5): 1618-28 e2[DOI][PubMed]
  • 11. Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandao-Mello CE, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009; 150(8): 528-40[PubMed]
  • 12. Camma C, Cabibbo G, Bronte F, Enea M, Licata A, Attanasio M, et al. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis. J Hepatol. 2009; 51(4): 675-81[DOI][PubMed]
  • 13. Lim JK, Imperial JC, Keeffe EB. Retreatment of chronic hepatitis C virus infection. Rev Gastroenterol Disord. 2004; 4(3): 97-103[PubMed]
  • 14. Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res. 1996; 16(7): 489-99[PubMed]
  • 15. Alavian SM, Behnava B, Tabatabaei SV. Comparative efficacy and overall safety of different doses of consensus interferon for treatment of chronic HCV infection: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2010; 66(11): 1071-9[DOI][PubMed]
  • 16. Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res. 1992; 12(1): 55-9[PubMed]
  • 17. Witthoft T. Review of consensus interferon in the treatment of chronic hepatitis C. Biologics. 2008; 2(4): 635-43[PubMed]
  • 18. Miglioresi L, Bacosi M, Russo F, Patrizi F, Saccenti P, Ursitti A, et al. Consensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infection. Hepatol Res. 2003; 27(4): 253-259[PubMed]
  • 19. Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, et al. Re-treatment of chronic hepatitis C with consensus interferon. Hepatology. 1998; 27(4): 1136-43[DOI][PubMed]
  • 20. Barbaro G, Barbarini G. Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study. Eur J Gastroenterol Hepatol. 2002; 14(5): 477-83[PubMed]
  • 21. Moskovitz DN, Manoharan P, Heathcote EJ. High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C. Can J Gastroenterol. 2003; 17(8): 479-82[PubMed]
  • 22. da Silva LC, Bassit L, Ono-Nita SK, Pinho JR, Nishiya A, Madruga CL, et al. High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study. J Gastroenterol. 2002; 37(9): 732-6[DOI][PubMed]
  • 23. Alaimo G, Di Marco V, Ferraro D, Di Stefano R, Porrovecchio S, D'Angelo F, et al. Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial. World J Gastroenterol. 2006; 12(42): 6861-4[PubMed]
  • 24. Bocher WO, Schuchmann M, Link R, Hillenbrand H, Rahman F, Sprinzl M, et al. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver Int. 2006; 26(3): 319-25[DOI][PubMed]
  • 25. Cornberg M, Hadem J, Herrmann E, Schuppert F, Schmidt HH, Reiser M, et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol. 2006; 44(2): 291-301[DOI][PubMed]
  • 26. Kaiser S, Hass HG, Gregor M. Successful retreatment of interferon/ribavirin nonresponders with daily dosing of consensus interferon. J Hepatol. 2005; 42: 207-208
  • 27. Jafri W, Subhan A. Hepatitis C in Pakistan: magnitude, genotype, disease characteristics and therapeutic response. Trop Gastroenterol. 2008; 29(4): 194-201[PubMed]
  • 28. Khan A, Tanaka Y, Azam Z, Abbas Z, Kurbanov F, Saleem U, et al. Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan. J Med Virol. 2009; 81(7): 1189-97[DOI][PubMed]
  • 29. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24(2): 289-93[DOI][PubMed]
  • 30. U.S. Department of Health and Human Services NIoH , National Cancer Institute . Common Terminology Criteria for Adverse Events v4.03 (CTCAE)..
  • 31. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54(4): 1433-44[DOI][PubMed]
  • 32. Fattovich G, Zagni I, Minola E, Felder M, Rovere P, Carlotto A, et al. A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. J Hepatol. 2003; 39(5): 843-9[PubMed]
  • 33. Bacon BR, Shiffman ML, Mendes F, Ghalib R, Hassanein T, Morelli G, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009; 49(6): 1838-46[DOI][PubMed]
  • 34. Moore CM, George M, Van Thiel DH. Consensus interferon used to treat prior partial-responders to pegylated interferon plus ribavirin. Dig Dis Sci. 2011; 56(10): 3032-7[DOI][PubMed]
  • 35. Yee HS, Currie SL, Tortorice K, Cozen M, Shen H, Chapman S, et al. Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study. Dig Dis Sci. 2011; 56(8): 2439-48[DOI][PubMed]
  • 36. Leevy CB. Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin. Dig Dis Sci. 2008; 53(7): 1961-6[DOI][PubMed]
  • 37. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology. 2002; 36(5 Suppl 1)-34[DOI][PubMed]
  • 38. Mangia A. Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients. Liver Int. 2011; 31(1): 36-41[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader